Dasatinib
Acinar Cell Adenocarcinoma of the Pancreas
Translational Oncology Research InternationalSmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Acinar Cell Adenocarcinoma of the Pancreas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Yale University | Phase 2 | BBB |
FLUOROURACILUM Yale University | Phase 2 | BBB |
Irinotecan Artios Pharma Ltd | Phase 2 | BB |
Metformin Case Comprehensive Cancer Center | Phase 2 | BB |
Bryostatin 1 National Cancer Institute (NCI) | Phase 2 | B |
View all 34 →
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →